State of Wisconsin Investment Board

Allen Control Systems is a defense technology company developing counter-drone robotic gun systems to usher in a new era of drone warfare and fundamentally alter battlefield economics.

Altriarch is an asset management firm based in Charleston, South Carolina, established in 2018. It operates as an alternative investment platform, specializing in targeted market niches to achieve strong risk-adjusted returns. Altriarch provides asset-based credit solutions tailored for lenders and small businesses, emphasizing a focused investment strategy that seeks to meet the unique needs of its clients.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

EatStreet is an online and mobile food ordering service that streamlines commerce between restaurants and diners. To college students and young professionals, EatStreet is a smart, simple, and affordable way to order delivery and takeout from their favorite restaurants. To restaurant owners, EatStreet is a one-stop-shop for online ordering and marketing. By providing web, mobile, and social products for online ordering, EatStreet brings in new business for restaurants. Diners enjoy the upside of fast, simple ordering while restaurants see their sales soar. Founded in 2010, the company is headquartered in Madison, Wisconsin, United States.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Rentable is an internet company founded in 2011 and based in Madison, Wisconsin, that focuses on enhancing the apartment rental search experience. Its web-based platform offers users a variety of tools, including localized flat listings, map-based searches, and shortlisting features, allowing for easy navigation through available properties. Additionally, Rentable provides an affordability calculator to assist users in determining suitable rental options based on their budget. By leveraging modern technology and an intuitive user interface, Rentable aims to streamline the process of finding apartments, making it more efficient and user-friendly for individuals seeking rental accommodations.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in developing therapeutic plasmid DNA vaccines targeting prostate cancer and bone metastases. The company is focused on creating two distinct vaccines designed for patients with prostate cancer, along with a diagnostic test aimed at identifying those who would benefit most from these therapies. Madison Vaccines' immune-activating therapies work by stimulating the immune system to eliminate residual tumor cells, thereby preventing the progression to bone metastases and delaying the need for more invasive treatments such as castration therapies. This approach aims to improve patient outcomes and enhance quality of life by facilitating earlier interventions in the cancer treatment process.

Zurex Pharma, Inc. is a pharmaceutical and medical technology company based in Middleton, Wisconsin, focused on developing and commercializing antimicrobial products aimed at preventing healthcare-associated infections, particularly in surgical site wounds and catheter-related infections. The company’s product lineup includes ZuraPrep, a pre-surgical skin preparation designed to prevent surgical site infections; ZurAsept, an antimicrobial and antithrombotic solution for catheters that helps reduce catheter-related bloodstream infections; and ZuraGard, which protects against exit site wounds. Founded in 2008, Zurex Pharma operates as a subsidiary of Ash Access Technology, Inc., and is dedicated to addressing the challenges of infection control in healthcare settings.

Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

EatStreet is an online and mobile food ordering service that streamlines commerce between restaurants and diners. To college students and young professionals, EatStreet is a smart, simple, and affordable way to order delivery and takeout from their favorite restaurants. To restaurant owners, EatStreet is a one-stop-shop for online ordering and marketing. By providing web, mobile, and social products for online ordering, EatStreet brings in new business for restaurants. Diners enjoy the upside of fast, simple ordering while restaurants see their sales soar. Founded in 2010, the company is headquartered in Madison, Wisconsin, United States.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in developing therapeutic plasmid DNA vaccines targeting prostate cancer and bone metastases. The company is focused on creating two distinct vaccines designed for patients with prostate cancer, along with a diagnostic test aimed at identifying those who would benefit most from these therapies. Madison Vaccines' immune-activating therapies work by stimulating the immune system to eliminate residual tumor cells, thereby preventing the progression to bone metastases and delaying the need for more invasive treatments such as castration therapies. This approach aims to improve patient outcomes and enhance quality of life by facilitating earlier interventions in the cancer treatment process.

Montage is the single solution to engage, interview, and hire better candidates, faster. The company partners with many of the world’s most well-respected brands, including 100 of the Fortune 500, to create the high-tech, high-touch hiring experience the modern candidate expects. As the pioneer of purpose-built video interviewing, its proprietary technology integrates seamlessly with enterprise needs for reliability, scalability, compliance, and security. Montage is committed to market-driven innovation, incorporating applicable science, and data in its solutions to speed the process and improve the predictability of talent acquisition. Its commitment to superior client service and support is unique in the industry. The company helps each and every client at every stage of our partnership because we sincerely want them to succeed – and believe in building relationships for the long term. A privately held company, Montage is headquartered in Wisconsin.

Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for central nervous system disorders. Established in 2009, the company is dedicated to addressing significant unmet medical needs, particularly in major depressive disorder (MDD) and alcohol use disorder (AUD). Euthymics is advancing its lead product, EB-1010, aimed at improving treatment outcomes for patients with depression who do not respond adequately to standard therapies such as selective serotonin reuptake inhibitors (SSRIs). This treatment seeks to enhance efficacy while minimizing common side effects associated with traditional antidepressants, including weight gain and sexual dysfunction. Additionally, Euthymics is exploring therapeutic options for smoking cessation and impulsivity, targeting withdrawal symptoms and cravings in affected individuals.

Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.

Caden Biosciences is a life sciences tools and services company focuses on G-protein coupled receptors (GPCRs).

Pinstripe is a top RPO provider with global reach and high customer satisfaction as recognized by HRO Today’s Baker’s Dozen. They serve world-class organizations in financial services, healthcare, pharmaceuticals, technology, advanced manufacturing, biotech, telecommunications and energy.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to combat infectious diseases in the United States and internationally. The company offers a range of products, including the Acuitas AMR Gene Panel for detecting bacterial nucleic acids and genetic markers of antimicrobial resistance, as well as QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to enhance management of multidrug-resistant organisms (MDROs). OpGen collaborates with the New York State Department of Health to devise solutions for tracking and managing antimicrobial-resistant infections in healthcare settings. Founded in 2001 and based in Gaithersburg, Maryland, the company aims to improve patient outcomes and reduce the spread of infections through rapid and actionable diagnostic information.

ZyStor Therapeutics, Inc. is a privately-held biotechnology company focused on developing enzyme replacement therapies for lysosomal storage diseases. The company specializes in creating innovative replacement technologies that enhance the delivery of therapeutics designed to substitute for missing lysosomal enzymes. These therapies aim to address the needs of patients suffering from genetic disorders characterized by lysosomal storage dysfunction.

Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Cardiac Pathways Corp manufactures minimally-invasive systems used by electrophysiologists to diagnose and treat cardiac tachyarrhythmia (abnormally rapid heart rhythms), which if untreated can cause palpitations, fainting, and sudden cardiac arrest. Cardiac Pathways' products consist principally of systems for performing ablation treatment (a nonsurgical, minimally-invasive technique for neutralizing heart tissue responsible for starting or maintaining a tachyarrhythmia) and for diagnostic mapping (locating the source of the tachyarrhythmia within the heart). Cardiac Pathways was issued a U.S. patent related to its Real-time Position Management Tracking System. Founded in 1991, Cardiac Pathways is based in Sunnyvale, California. As of August 6, 2001, it was acquired by Boston Scientific Corporation.